K-7174

K-7174

Catalog Number:
L002371315APE
Mfr. No.:
APE-B5898
Price:
$276
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Description:
          IC50: 9 μM
          The main function of the proteasome is to degrade unneeded or damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. Proteasome inhibition is now considered a unique and effective way to kill cancer cells that can tolerate conventional chemotherapy. K-7174 is a novel orally active proteasome inhibitor.
          In vitro: Due to its proteasome inhibitary effect, K-7174 induces transcriptional repression of class I histone deacetylases (HDAC) via caspase-8-dependent degradation of Sp1, the most potent transactivator of class I HDAC genes. HDAC1 overexpression reduces the cytotoxic effect of K-7174 and abrogates histone hyperacetylation without affecting the ubiquitinated protein accumulation in K-7174-treated myeloma cells [1].
          In vivo: K-7174 exhibits the therapeutic effects through its anti-proteasome activities, which is stronger when administered orally than intravenously, without obvious side effects in a murine myeloma model. In addition, K-7174 kills bortezomib-resistant myeloma cells carrying a β5-subunit mutation in vivo and primary cells from a patient resistant to bortezomib [1].
          Clinical trial: Up to now, K-7174 is still in the preclinical development stage.

      • Properties
        • Alternative Name
          1,4-bis((E)-5-(3,4,5-trimethoxyphenyl)pent-4-en-1-yl)-1,4-diazepane dihydrochloride
          CAS Number
          191089-60-8
          Molecular Formula
          C33H50Cl2N2O6
          Molecular Weight
          641.67
          Purity
          98.00%
          Solubility
          ≥64.2 mg/mL in H2O; ≥51.6 mg/mL in EtOH; ≥61.8 mg/mL in DMSO
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Martinez-H?yer S, Deng Y, et al. "Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome." Nat Cell Biol. 2020;22(5):526-533. PMID:32251398

    We Also Recommend

    LED209

    $172

    Note: If you don't receive our verification email, do the following:

  • Copyright © Amerigo Scientific. All rights reserved.